Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection

被引：0

作者：

Wendel, Sarah K. ^{[1
]}

Longosz, Andrew F. ^{[2
]}

Eshleman, Susan H. ^{[3
]}

Blankson, Joel N. ^{[2
]}

Moore, Richard D. ^{[2
]}

Keruly, Jeanne C. ^{[2
]}

Quinn, Thomas C. ^{[1
,2
]}

Laeyendecker, Oliver ^{[1
,2
]}

机构：

[1] NIAID, Lab Immunoregulat LIR, NIH, 855 North Wolfe St,Room 538A, Baltimore, MD 21205 USA

[2] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA

[3] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2017年 / 33卷 / 04期

基金：

美国国家卫生研究院;

关键词：

viral suppression; HIV; LAg; ART; IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; SEROCONVERSION;

D O I：

10.1089/aid.2016.0105

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We analyzed the impact of HIV viral load on the performance of a limiting antigen avidity enzyme immunoassay (LAg-Avidity assay) and determined if this assay could be used to identify viral breakthrough. Three groups of samples were tested: (1) 18 individuals (30 samples) previously identified as elite suppressors; (2) 18 individuals (72 samples) who were continually suppressed on antiretroviral treatment (ART) with 1 sample before and 2-6 samples (one/year) after ART initiation; and (3) 20 individuals (179 samples) on ART who had evidence of viral breakthrough (>400 copies/ml) with subsequent viral suppression. Elite suppressors had the lowest LAg-Avidity assay values. Among those who were continually suppressed on ART, 83% (15/18) had LAg-Avidity assay values that decreased over time. Although the LAg-Avidity assay on a single sample cannot identify when a viral breakthrough occurs, paired longitudinal samples could identify viral breakthrough (sensitivity: 65%, specificity: 84%).

引用

页码：325 / 327

页数：3

共 2 条

[1] Effect of Natural and ARV-Induced Viral Suppression and Viral Breakthrough on Anti-HIV Antibody Proportion and Avidity in Patients with HIV-1 Subtype B Infection
Wendel, Sarah K.
Mullis, Caroline E.
Eshleman, Susan H.
Blankson, Joel N.
Moore, Richard D.
Keruly, Jeanne C.
Brookmeyer, Ron
Quinn, Thomas C.
Laeyendecker, Oliver
PLOS ONE, 2013, 8 (02):
[2] Short Communication: False Recent Ratio of the Limiting-Antigen Avidity Assay and Viral Load Testing Algorithm Among Cameroonians with Long-Term HIV Infection
Lynch, Briana A.
Patel, Eshan U.
Courtney, Colleen R.
Nanfack, Aubin J.
Bimela, Jude
Wang, Xiaohong
Eid, Issa
Quinn, Thomas C.
Laeyendecker, Oliver
Nyambi, Phillipe N.
Duerr, Ralf
Redd, Andrew D.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2017, 33 (11) : 1114 - 1116

← 1 →